查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1606885

广泛的小细胞肺癌市场：按治疗方式、药物类型、给药途径、分销管道划分 - 全球预测 2025-2030

Extensive Stage Small Cell Lung Cancer Market by Treatment Modalities (Chemotherapy, Combination Therapies, Immunotherapy), Drug Type (Atezolizumab, Durvalumab, Etoposide), Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

广泛的小细胞肺癌市场2023年估值为47.5亿美元，预计2024年将达到54亿美元，复合年增长率为12.63%，预计到2030年将达到109.2亿美元。

广泛性小细胞肺癌（ES-SCLC）是一种晚期小细胞肺癌，其特征是侵袭性生长和广泛扩散到半胸部以外，常导致远处器官的侵袭。 ES-SCLC 治疗和诊断市场是由全球肺癌盛行率不断上升以及鑑于与这种疾病相关的有限生存率而迫切需要有效的治疗方案所推动的。癌症细胞的预后极差和快速进化的性质推动了对治疗创新的需求，这使得免疫查核点抑制剂、标靶治疗和先进药物输送系统等新型疗法的应用成为一个领域。这些创新对于以患者为中心的护理以及製药和生物技术行业扩大其肿瘤产品组合的更广泛努力至关重要。影响这个市场的关键成长要素包括分子生物学和基因组学的进步，这些进步使得客製化治疗和伴同性诊断成为可能，以及政府和私人组织在癌症研究方面的支出增加，其中一个例子是投资。至于潜在的商机，人工智慧驱动的诊断工具和个人化医疗等新技术为改善患者治疗结果和简化药物开发流程指明了道路。然而，高昂的研发成本、严格的监管要求以及个人化治疗通讯协定的复杂性等挑战构成了主要障碍。市场相关人员应专注于协作研究和伙伴关係，以缓解这些挑战并共用专业知识。创新应优先发展微创诊断技术和将新分子标靶与现有治疗方法结合的联合治疗。此外，提高新兴国家最先进治疗的可近性和可负担性是市场开拓的关键方面。该市场的特点是技术创新的快速週期和不断变化的竞争格局，要在这种动态格局中保持领先地位，需要采取积极主动的方法来获取市场情报。

主要市场统计
基准年[2023] 47.5亿美元
预计年份 [2024] 54亿美元
预测年份 [2030] 109.2亿美元
复合年增长率（%） 12.63%

市场动态：针对快速发展的广泛小细胞肺癌市场揭示的关键市场见解

供需的动态交互作用正在改变广谱小细胞肺癌市场。了解这些不断变化的市场动态可以帮助组织做出明智的投资决策、改善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 全球小细胞肺癌的盛行率不断上升
    • 加强医疗保健意识不断增强
    • 政府不断采取倡议广泛治疗小细胞肺癌
  • 市场限制因素
    • 学名药氾滥
  • 市场机会
    • 增加新治疗方法研究和开发领域的资金
    • 广谱小细胞肺癌筛检程序的技术进步
  • 市场挑战
    • 放射线治疗和化疗副作用的风险

波特五力：驾驭广泛的小细胞肺癌市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解广泛的小细胞肺癌市场的外部影响

外部宏观环境因素在塑造广谱小细胞肺癌市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解广泛的小细胞肺癌市场的竞争格局

对广泛的小细胞肺癌市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵广泛小细胞肺癌市场供应商的绩效评估

FPNV定位矩阵是评估广谱小细胞肺癌市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了在广泛的小细胞肺癌市场中的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对广泛的小细胞肺癌市场进行策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球小细胞肺癌盛行率普遍上升
      • 加强医疗照护的意识不断增强
      • 政府加大对广泛小细胞肺癌治疗的承诺
    • 抑制因素
      • 学名药供应充足
    • 机会
      • 增加新疗法研究和开发的资金
      • 广谱小细胞肺癌筛检程序的技术进步
    • 任务
      • 放疗和化疗副作用的风险
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗方法分類的广泛小细胞肺癌市场

  • 化疗
  • 联合治疗
  • 免疫疗法
  • 放射治疗
  • 标靶治疗

第七章按药物类型分類的广泛小细胞肺癌市场

  • Atezolizumab
  • Durvalumab
  • Etoposide
  • 鲁宾内克丁
  • 胺基甲基叶酸
  • Pembrolizumab
  • 拓扑替康

第八章广泛的小细胞肺癌市场：依给药途径

  • 口服
  • 胃肠外的

第九章广泛的小细胞肺癌市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第10章：北美和南美广泛的小细胞肺癌市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区广泛的小细胞肺癌市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第12章：欧洲、中东和非洲广泛的小细胞肺癌市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly & Company Ltd.
  • Exelixis, Inc.
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Nektar Therapeutics
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
Product Code: MRR-2E76C3E47FB9

The Extensive Stage Small Cell Lung Cancer Market was valued at USD 4.75 billion in 2023, expected to reach USD 5.40 billion in 2024, and is projected to grow at a CAGR of 12.63%, to USD 10.92 billion by 2030.

Extensive Stage Small Cell Lung Cancer (ES-SCLC) refers to a late-stage classification of small cell lung cancer characterized by aggressive growth and widespread dissemination beyond the hemi-thorax, often leading to involvement of distant organs. The market for treatments and diagnostics for ES-SCLC is driven by the increasing prevalence of lung cancer worldwide and the urgent need for effective therapeutic options, given the limited survival rates associated with the disease. The necessity of treatment innovations lies in the dire prognosis and the rapidly evolving nature of the cancer cells, making this area ripe for the application of novel therapeutics such as immune checkpoint inhibitors, targeted therapies, and advanced drug delivery systems. These innovations are pivotal for both patient-centric treatments and the broad scope of pharmaceutical and biotech industries seeking to expand their oncology portfolios. Key growth factors influencing this market include advancements in molecular biology and genomics, enabling more tailored therapies and companion diagnostics, as well as significant investments in cancer research by governmental and private entities. As potential opportunities, emerging technologies such as AI-driven diagnostic tools and personalized medicine present avenues for enhanced patient outcomes and streamlined drug development processes. However, challenges such as the high costs of R&D, stringent regulatory requirements, and the complexity of personalized treatment protocols pose significant barriers. Market players should focus on collaborations and partnerships to mitigate these challenges and leverage shared expertise. Innovation should prioritize the development of minimally invasive diagnostic techniques and combination therapies that integrate new molecular targets with established treatment regimes. Additionally, increasing accessibility and affordability of cutting-edge treatments in developing countries represents a crucial aspect of market expansion. The nature of this market is characterized by rapid innovation cycles and competitive advancements, necessitating a proactive approach to market intelligence to stay ahead in this dynamic landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 4.75 billion
Estimated Year [2024] USD 5.40 billion
Forecast Year [2030] USD 10.92 billion
CAGR (%) 12.63%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Extensive Stage Small Cell Lung Cancer Market

The Extensive Stage Small Cell Lung Cancer Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in prevalence of extensive stage small cell lung cancer across the globe
    • Growing awareness regarding enhanced health care
    • Rising government initiatives for extensive stage small cell lung cancer treatment
  • Market Restraints
    • Huge availability of the generic drugs
  • Market Opportunities
    • Increasing funding in the field of research and development of new treatment
    • Technological advancement in the extensive stage small cell lung cancer screening procedures
  • Market Challenges
    • Risk of side effects of radiation and chemotherapy

Porter's Five Forces: A Strategic Tool for Navigating the Extensive Stage Small Cell Lung Cancer Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Extensive Stage Small Cell Lung Cancer Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Extensive Stage Small Cell Lung Cancer Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Extensive Stage Small Cell Lung Cancer Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Extensive Stage Small Cell Lung Cancer Market

A detailed market share analysis in the Extensive Stage Small Cell Lung Cancer Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Extensive Stage Small Cell Lung Cancer Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Extensive Stage Small Cell Lung Cancer Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Extensive Stage Small Cell Lung Cancer Market

A strategic analysis of the Extensive Stage Small Cell Lung Cancer Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Extensive Stage Small Cell Lung Cancer Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly & Company Ltd., Exelixis, Inc., F. Hoffmann-La Roche AG, Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Incyte Corporation, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson & Johnson Services, Inc., Merck KGaA, Nektar Therapeutics, Novartis AG, Pfizer, Inc., Sanofi S.A., and Takeda Pharmaceutical Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Extensive Stage Small Cell Lung Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Modalities, market is studied across Chemotherapy, Combination Therapies, Immunotherapy, Radiation Therapy, and Targeted Therapies.
  • Based on Drug Type, market is studied across Atezolizumab, Durvalumab, Etoposide, Lurbinectedin, Methotrexate, Pembrolizumab, and Topotecan.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in prevalence of extensive stage small cell lung cancer across the globe
      • 5.1.1.2. Growing awareness regarding enhanced health care
      • 5.1.1.3. Rising government initiatives for extensive stage small cell lung cancer treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Huge availability of the generic drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing funding in the field of research and development of new treatment
      • 5.1.3.2. Technological advancement in the extensive stage small cell lung cancer screening procedures
    • 5.1.4. Challenges
      • 5.1.4.1. Risk of side effects of radiation and chemotherapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Extensive Stage Small Cell Lung Cancer Market, by Treatment Modalities

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Combination Therapies
  • 6.4. Immunotherapy
  • 6.5. Radiation Therapy
  • 6.6. Targeted Therapies

7. Extensive Stage Small Cell Lung Cancer Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Atezolizumab
  • 7.3. Durvalumab
  • 7.4. Etoposide
  • 7.5. Lurbinectedin
  • 7.6. Methotrexate
  • 7.7. Pembrolizumab
  • 7.8. Topotecan

8. Extensive Stage Small Cell Lung Cancer Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral

9. Extensive Stage Small Cell Lung Cancer Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Extensive Stage Small Cell Lung Cancer Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Extensive Stage Small Cell Lung Cancer Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Extensive Stage Small Cell Lung Cancer Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Boehringer Ingelheim GmbH
  • 6. Bristol Myers Squibb Company
  • 7. Celgene Corporation
  • 8. Daiichi Sankyo Company, Limited
  • 9. Eisai Co., Ltd.
  • 10. Eli Lilly & Company Ltd.
  • 11. Exelixis, Inc.
  • 12. F. Hoffmann-La Roche AG
  • 13. Genentech, Inc.
  • 14. Gilead Sciences, Inc.
  • 15. GlaxoSmithKline PLC
  • 16. Incyte Corporation
  • 17. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • 18. Johnson & Johnson Services, Inc.
  • 19. Merck KGaA
  • 20. Nektar Therapeutics
  • 21. Novartis AG
  • 22. Pfizer, Inc.
  • 23. Sanofi S.A.
  • 24. Takeda Pharmaceutical Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET RESEARCH PROCESS
  • FIGURE 2. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET DYNAMICS
  • TABLE 7. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ETOPOSIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY LURBINECTEDIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TOPOTECAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 197. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2023